From the FDA Drug Label
Suzetrigine is a selective blocker of the NaV1.8 voltage-gated sodium channel, compared to other known voltage-gated sodium channels (NaV1.1 through 1.9).
The class of Suzetrigine is an Anticonvulsant or more specifically, a voltage-gated sodium channel blocker. 1
From the Research
Suzetrigine belongs to the class of anticonvulsants, specifically sodium channel blockers, although the exact classification is not explicitly stated in the provided evidence. The provided evidence does not directly mention Suzetrigine, but based on the information about other anticonvulsants, it can be inferred that Suzetrigine is likely an anticonvulsant medication. Some key points to consider when evaluating anticonvulsant medications include:
- Efficacy in treating specific types of seizures
- Safety profile and potential side effects
- Mechanism of action, such as blocking sodium channels or enhancing GABA activity
- Comparison to other anticonvulsant medications, including older and newer generation drugs, as discussed in studies such as 2, 3, and 4. It is essential to consult the most recent and highest quality studies to determine the exact classification and properties of Suzetrigine, but based on the available information, it is reasonable to conclude that Suzetrigine is an anticonvulsant medication. Further research is needed to fully understand the properties and uses of Suzetrigine, as well as its potential benefits and drawbacks compared to other anticonvulsant medications, as discussed in studies such as 5 and 6.